neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation.
- 1 November 1988
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 85 (21) , 8057-8061
- https://doi.org/10.1073/pnas.85.21.8057
Abstract
The protein encoded by the neu protooncogene (human gene symbol NGL for neuro/glioblastoma-derived) is a member of the surface receptor/tyrosine kinase family. Though its structure suggests that it can transduce a transmembrane signal, neither its extracellular ligand nor its critical intracellular substrates are known. To explore the functional properties of the protein encoded by neu, we created a fusion gene that joins the cytoplasmic domain of neu to the extracellular portion of an immunoglobulin heavy chain. The localization of the fusion polypeptide can then be controlled by coexpression with immunoglobulin light chain. In the absence of light chain, the heavy chain-neu polypeptide is expressed intracellularly and has no transforming activity. By contrast, in the presence of light chain the fusion polypeptide is expressed at the cell surface and produces tumorigenic foci. Thus, transformation apparently requires expression at the cell surface, where the neu intracellular domain can interact with components that are localized to the plasma membrane. The fusion protein is active in cellular transformation when the transmembrane domain is derived either from neu or from immunoglobulin, indicating that the neu transmembrane domain is not specifically required for transformation, although neu activation in tumors is known to result from a point mutation in this region. The extracellular immunoglobulin heavy and light chain domains of the fusion protein form a functional binding site that allows antigen to modulate its activity, reversing the transforming effect.This publication has 33 references indexed in Scilit:
- RECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENSAnnual Review of Biochemistry, 1987
- Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells.Journal of Biological Chemistry, 1984
- Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequencesNature, 1984
- Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenesNature, 1983
- Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies.Journal of Biological Chemistry, 1983
- Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.1982
- Nucleic acid and protein sequences of phosphocholine-binding light chains.The Journal of Experimental Medicine, 1981
- Synthesis of immunoglobulin mu chain gene products precedes synthesis of light chains during B-lymphocyte development.Proceedings of the National Academy of Sciences, 1981
- Induction of clonally restricted thymus-dependent antibody responses in vitro using phosphorylcholine derivatized sheep erythrocytesJournal of Immunological Methods, 1980
- Transformation of mammalian cells with genes from procaryotes and eucaryotesCell, 1979